As MET oncogene amplification has been implicated in both primary and acquired resistance to EGFR inhibition 54, MET inhibitors are being studied in combination with erlotinib for molecularly selected, advanced NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.